Use of Letermovir as Secondary Prophylaxis in Cytomegalovirus Resistant Pediatric Heart Transplant Recipients
In our experience, letermovir was well tolerated and effective in the management of resistant CMV in pediatric heart transplant recipients.
Authors
- Varvara Probst (ORCID: https://orcid.org/0000-0003-4633-8552)
- Dipankar Gupta (ORCID: https://orcid.org/0000-0003-0143-7143)
- Debbie‐Ann Shirley (ORCID: https://orcid.org/0000-0003-1718-0901)
- Emily C. Martin (ORCID: https://orcid.org/0000-0002-2011-3905)
- John‐Anthony Coppola (ORCID: https://orcid.org/0009-0009-4291-4373)
Institutions
- University of Florida Health (US)
- University of Florida (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2025-05-28
- DOI
- https://doi.org/10.1111/ctr.70187
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00